0000899243-21-021651.txt : 20210602 0000899243-21-021651.hdr.sgml : 20210602 20210602200215 ACCESSION NUMBER: 0000899243-21-021651 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210601 FILED AS OF DATE: 20210602 DATE AS OF CHANGE: 20210602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith-Whitley Kim CENTRAL INDEX KEY: 0001860297 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 21990867 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 181 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001860297 Smith-Whitley Kim C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Restricted Stock Units 2021-06-01 4 A 0 24160 0.00 A Common Stock 24160 24160 D Restricted Stock Units 2021-06-01 4 A 0 6300 0.00 A Common Stock 6300 6300 D Stock Option (Right to Buy) 37.20 2021-06-01 4 A 0 35500 0.00 A 2031-05-31 Common Stock 35500 35500 D Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. The RSUs vest with respect to 25% of the underlying shares on June 1, 2022 and in six semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The stock option vests with respect to 25% of the underlying shares on May 3, 2022 and in 12 equal quarterly installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Title: EVP, Head of Research & Development /s/ Tricia Suvari , Attorney-in-Fact 2021-06-02